MENLO PARK, Calif., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today reported financial results for the quarter ended June 30, 2016 and provided an update on its clinical development programs.
“Our progress continued in the second quarter with the announcement of favorable results for our DRM01 Phase 2b and DRM04 Phase 3 clinical programs and a successful financing in which we raised net proceeds of approximately $136 million,” said Tom Wiggans, chairman and chief executive officer of Dermira. “As we look forward to the second half of the year, we expect to announce topline results for our CIMZIA Phase 3 clinical program beginning in the fourth quarter. We will also be preparing for our Phase 3 program for DRM01 as well as our pre-NDA meeting with the FDA for DRM04. With our balance sheet further strengthened as a result of our recent financing, we believe Dermira is well positioned to continue supporting our existing pipeline, while seeking to expand it with other innovative compounds.”
“Our progress continued in the second quarter with the announcement of favorable results for our DRM01 Phase 2b and DRM04 Phase 3 clinical programs and a successful financing in which we raised net proceeds of approximately $136 million,” said Tom Wiggans, chairman and chief executive officer of Dermira. “As we look forward to the second half of the year, we expect to announce topline results for our CIMZIA Phase 3 clinical program beginning in the fourth quarter. We will also be preparing for our Phase 3 program for DRM01 as well as our pre-NDA meeting with the FDA for DRM04. With our balance sheet further strengthened as a result of our recent financing, we believe Dermira is well positioned to continue supporting our existing pipeline, while seeking to expand it with other innovative compounds.”
